Literature DB >> 10796763

Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles.

S Daya1.   

Abstract

BACKGROUND: Gonadotropin releasing hormone agonists (GnRHa) are used in assisted reproduction cycles to reversibly block pituitary function and prevent a luteinizing hormone surge. In the short and ultrashort protocols of GnRHa administration, injection of gonadotropins is commenced a few days after the start of GnRHa. In the long protocols (with GnRHa started either in the midluteal phase or in the early follicular phase) gonadotropin administration is delayed until pituitary desensitization has been achieved, usually 2-3 weeks.
OBJECTIVES: To conduct a systematic overview of available data comparing short or ultrashort and long GnRHa protocols for pituitary desensitization in in vitro fertilization (IVF) and gamete intra-fallopian transfer (GIFT) treatment cycles. SEARCH STRATEGY: Search strategies included on-line searching of the MEDLINE and EMBASE data bases and the Cochrane Menstrual Disorders and Subfertility Group's Specialised Register from 1982 to 1998, and hand searching of bibliographies of relevant publications and reviews, and abstracts of scientific meetings. SELECTION CRITERIA: Randomized trials of short or ultrashort versus long (follicular or luteal phase start) GnRHa protocols in IVF or GIFT treatment cycles. DATA COLLECTION AND ANALYSIS: Data were extracted into 2 x 2 tables. For the primary outcome, clinical pregnancy per cycle started, the overall common odds ratio (OR) and the risk difference with 95% confidence interval (CI) were calculated after verifying the presence of homogeneity of treatment effect across all trials. The following subgroup comparisons were performed: ultrashort versus long protocols, short versus long protocols and, within each of these comparisons, subgroups of studies which used the long protocol with follicular phase start or the long protocol with luteal phase start. Secondary outcomes considered were clinical pregnancy per oocyte retrieval and per embryo transfer, spontaneous abortion, ongoing/delivered pregnancy per cycle started, number of ampoules of gonadotropin used, number of oocytes retrieved, and fertilization rate. MAIN
RESULTS: Twenty-six trials met the inclusion criteria. The common OR for clinical pregnancy per cycle started was 1.32 (95% CI, 1.10 - 1.57) in favour of the long GnRHa protocol. The studies were subgrouped, depending on whether, in the long protocol, the GnRHa was commenced in the follicular phase (8 trials) or luteal phase (16 trials). The respective ORs were 1.54 (95% CI, 1.11 - 2. 13) and 1.21 (95% CI, 0.98 - 1.51). After excluding the four trials using the ultrashort protocol, the OR for long versus short protocols (22 trials) was 1.27 (95% CI, 1.04 - 1.56). A comparison of long versus ultrashort protocols (4 trials) produced an OR of 1. 47 (95% CI, 1.02 - 2.12). REVIEWER'S
CONCLUSIONS: On the basis of clinical pregnancy rate per cycle started, this meta-analysis demonstrates the superiority of the long protocol over the short and ultrashort protocols for GnRHa use in IVF and GIFT cycles.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10796763     DOI: 10.1002/14651858.CD001299

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  14 in total

1.  The effects of GnRH antagonist on the endometrium of normally menstruating women.

Authors:  Porntip Sirayapiwat; Somchai Suwajanakorn; Surang Triratanachat; Somchai Niruthisard
Journal:  J Assist Reprod Genet       Date:  2007-11-30       Impact factor: 3.412

2.  Is there an ideal stimulation regimen for IVF for poor responders and does it change with age?

Authors:  Beverley Vollenhoven; Tiki Osianlis; James Catt
Journal:  J Assist Reprod Genet       Date:  2008-11-04       Impact factor: 3.412

3.  Does lower dose of long-acting triptorelin maintain pituitary suppression and produce good live birth rate in long down-regulation protocol for in-vitro fertilization?

Authors:  Xin Chen; Shu-Xian Feng; Ping-Ping Guo; Yu-Xia He; Yu-Dong Liu; De-Sheng Ye; Shi-Ling Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-04-13

Review 4.  Is ovulation induction still a therapeutic problem in patients with polycystic ovary syndrome?

Authors:  S Palomba; F Orio; T Russo; A Falbo; T Cascella; A Colao; G Lombardi; F Zullo
Journal:  J Endocrinol Invest       Date:  2004-09       Impact factor: 4.256

Review 5.  Comparison of different stimulation protocols used in in vitro fertilization: a review.

Authors:  Deekshya Shrestha; Xiaolin La; Huai L Feng
Journal:  Ann Transl Med       Date:  2015-06

6.  Effect of Progestin-primed Ovarian Stimulation Protocol on Outcomes of Aged Infertile Women Who Failed to Get Pregnant in the First IVF/ ICSI Cycle: A Self-controlled Study.

Authors:  Yin-Mei Chen; Qian-Rong Qi; Qing-Zhen Xie; Yi-Fan Yang; Yi Xia; Xiao-Dan Zhou
Journal:  Curr Med Sci       Date:  2018-06-22

Review 7.  Contemporary pharmacological manipulation in assisted reproduction.

Authors:  Judith A F Huirne; Cornelis B Lambalk; Andre C D van Loenen; Roel Schats; Peter G A Hompes; Bart C J M Fauser; Nick S Macklon
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  Gonadotropin-releasing hormone antagonists for assisted reproductive techniques: are there clinical differences between agents?

Authors:  Georg Griesinger; Ricardo E Felberbaum; Askan Schultze-Mosgau; Klaus Diedrich
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET).

Authors:  Raffaella Depalo; K Jayakrishan; Gabriella Garruti; Ilaria Totaro; Mariantonietta Panzarino; Francesco Giorgino; Luigi E Selvaggi
Journal:  Reprod Biol Endocrinol       Date:  2012-04-13       Impact factor: 5.211

Review 10.  Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization.

Authors:  Alberto Revelli; Simona Casano; Francesca Salvagno; Luisa Delle Piane
Journal:  Reprod Biol Endocrinol       Date:  2011-02-16       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.